Printer Friendly

SEARLE ANNOUNCES SPECIFICS OF DISCOUNT PRICING TO PUBLIC HEALTH SERVICE CLINICS

 SEARLE ANNOUNCES SPECIFICS OF DISCOUNT PRICING
 TO PUBLIC HEALTH SERVICE CLINICS
 CHICAGO, Feb. 3 /PRNewswire/ -- Searle announced today the specifics of the company's policy for offering discounted prices on its entire product line of prescription medications to health centers that are federally funded by the United States Public Health Service.
 "Searle was the first pharmaceutical manufacturer to respond to requests made by Senators Kennedy (D-Mass.) and Hatch (R-Utah) to offer discounted prices to Public Health Service-funded clinics back in November 1991," said Sheldon G. Gilgore, M.D., chairman of the board and chief executive officer of Searle. "Now that we've had some experience working with the various health centers funded by the Public Health Service, we are able to delineate the specifics of our discount program."
 Public Health Service clinics may make direct purchases at Searle's Federal Supply Schedule prices if they are principally tax-supported; receive at least 25 percent of their funding from the Public Health Service; and disclose complete information on Medicaid-reimbursed utilization for which best prices have already been provided through rebates to state Medicaid agencies. In addition, Searle plans to review prospective clinics on an individual basis to ensure that no particular clinic is rejected arbitrarily as a result of the criteria established.
 "This program joins the Searle Patients in Need(R) program and other ongoing Searle initiatives aimed at ensuring the availability of quality health care for all patients," said Gilgore. Through Patients in Need, Searle has provided nearly 900,000 prescriptions free-of-charge to patients unable to afford them and who do not have any form of health insurance. This represents an expenditure of over $27 million by Searle.
 Searle is a research-based pharmaceutical company that develops, manufactures and markets pharmaceutical products worldwide. It is a wholly owned subsidiary of Monsanto Company (NYSE: MTC).
 -0- 2/3/92
 /CONTACT: Laura Leber of Searle, 708-470-6280/
 (MTC) CO: Searle; Monsanto Company ST: Illinois, Missouri IN: MTC SU:


JT -- NY102 -- 6407 02/03/92 17:25 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 3, 1992
Words:329
Previous Article:IONICS ANNOUNCES PRICING OF 1 MILLION SHARES OF COMMON STOCK AT $49-3/8 PER SHARE
Next Article:LONE STAR STEAKHOUSE & SALOON ANNOUNCES INITIAL PUBLIC OFFERING
Topics:


Related Articles
BRISTOL-MYERS SQUIBB ANNOUNCES VOLUNTARY REDUCTION IN PHARMACEUTICAL PRICES TO FEDERAL GOVERNMENT
BRISTOL-MYERS SQUIBB ANNOUNCES VOLUNTARY REDUCTION IN PHARMACEUTICAL PRICES TO FEDERAL GOVERNMENT
SYNTEX EXTENDS DISCOUNTED PRICES TO FEDERALLY FUNDED PUBLIC HEALTH SERVICE CENTERS
GLAXO TO OFFER PRICE DISCOUNTS TO PUBLIC HEALTH CLINICS
PFIZER ANNOUNCES SUPPORT FOR KENNEDY/HATCH BILL THAT WOULD PROVIDE DRUG DISCOUNTS TO PUBLIC HEALTH CLINICS
BURROUGHS WELLCOME VOLUNTARILY REDUCES PRESCRIPTION DRUG PRICES TO FEDERALLY FUNDED PUBLIC HEALTH CLINICS AND GOVERNMENT AGENCIES USING FSS
SANDOZ ANNOUNCES PRICE REDUCTION TO VETERANS ADMINISTRATION, PUBLIC HEALTH SERVICE AND OTHER FEDERAL CLINICS
POLL SHOWS CONSUMERS TO BE WARY OF CONTROLLING HEALTH-CARE COSTS BY CUTTING TECHNOLOGY
COCENSYS AND SEARLE TO COLLABORATE ON DEVELOPMENT/MARKETING OF NOVEL INSOMNIA TREATMENT
Summer price spike: a case study about publicly funded clinics and the cost of contraceptive supplies.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters